Professor of Child Health, School of Medicine
Professor of Molecular Microbiology and Immunology, School of Medicine
NextGen Focus Area: Cancer
The primary focus of Dr. Shirwan’s translational research program is to develop safe and practical approaches to modulate the immune system for the treatment of immune-based disorders. He co-pioneered with his colleague Esma S. Yolcu, PhD, a proprietary platform known as ProtExTM that allows for the generation of novel recombinant immune ligands and their positional display on biological surfaces as a practical and safe alternative to gene therapy for localized immunomodulation with application to transplantation, autoimmunity, cancer, and infections.
Precision Health Impact:
- Using precision medicine to identify immune pathways with druggable targets for the prevention and treatment of cancer, type 1 diabetes, and transplant rejection
- Generate novel biologics to druggable immune pathways and employ different vehicles, such as live bacteria and nanoparticles, for their targeted delivery to ensure efficacy and safety
Email: haval.shirwan@health.missouri.edu
Department website: https://medicine.missouri.edu/faculty/haval-shirwan-phd